Wolverine Trading, LLC Lexicon Pharmaceuticals, Inc. Put Options Transaction History

Wolverine Trading, LLC

17 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$1.51 - $2.39 $11,023 - $17,447	-7,300 Reduced 42.2%	10,000 $15,000
Q2 2024 Aug 14, 2024	SELL	$1.54 - $2.28 $5,698 - $8,436	-3,700 Reduced 17.62%	17,300 $29,000
Q1 2024 May 15, 2024	BUY	$1.3 - $3.58 $11,310 - $31,146	8,700 Added 70.73%	21,000 $50,000
Q4 2023 Feb 14, 2024	SELL	$1.0 - $1.53 $1,100 - $1,683	-1,100 Reduced 8.21%	12,300 $18,000
Q3 2023 Nov 15, 2023	SELL	$1.06 - $2.33 $14,310 - $31,455	-13,500 Reduced 50.19%	13,400 $14,000
Q2 2023 Aug 23, 2023	BUY	$2.15 - $3.49 $57,835 - $93,881	26,900 New	26,900 $61,000
Q4 2021 Feb 14, 2022	BUY	$3.81 - $6.16 $38,862 - $62,832	10,200 Added 69.39%	24,900 $104,000
Q3 2021 Nov 12, 2021	BUY	$3.38 - $5.35 $9,464 - $14,979	2,800 Added 23.53%	14,700 $72,000
Q2 2021 Aug 06, 2021	BUY	$4.12 - $5.87 $49,028 - $69,853	11,900 New	11,900 $60,000
Q1 2020 May 11, 2020	SELL	$1.8 - $4.28 $19,620 - $46,652	-10,900 Closed	0 $0
Q4 2019 Feb 12, 2020	SELL	$3.16 - $5.15 $27,176 - $44,290	-8,600 Reduced 44.1%	10,900 $45,000
Q3 2019 Nov 14, 2019	SELL	$1.2 - $6.66 $10,920 - $60,606	-9,100 Reduced 31.82%	19,500 $67,000
Q2 2019 Aug 20, 2019	SELL	$5.35 - $7.11 $193,135 - $256,671	-36,100 Reduced 55.8%	28,600 $180,000
Q1 2019 May 15, 2019	BUY	$4.36 - $7.94 $282,092 - $513,718	64,700 New	64,700 $360,000
Q3 2018 Nov 14, 2018	SELL	$10.32 - $13.06 $180,600 - $228,550	-17,500 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$7.86 - $11.39 $3,930 - $5,695	500 Added 2.94%	17,500 $150,000
Q3 2017 Nov 15, 2017	BUY	$12.17 - $16.3 $206,890 - $277,100	17,000	17,000 $209,000

141

238M

459K

133K

Ticker LXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,726,000
Market Cap $134M
Description
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; ...

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Wolverine Trading, LLC with notifications on news.